UK Industry Prepares For Post-COVID-19 ‘Normal’ As Non-Urgent And Planned Elective Care Get Green Light
Executive Summary
Non-urgent care, ceased by the UK government after the initial surge of COVID-19 cases, is to be restored gradually now that the virus has peaked and new cases are falling. The UK ABHI’s Andrew Davies explains what this means for the medtech industry.
You may also be interested in...
‘Restarting Is Harder Than Stopping’: UK Elective Care Faces Challenges Beyond COVID-19
Elective surgery is only “elective” in terms of timing, and is not optional. So says British Orthopaedic Association VP-elect John Skinner in the context of how post-COVID-19 planned care will move forward in the UK.
Fact File: European COVID-19 Focus Shifts To Managing The ‘New Normal’
The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.
UK Life Sciences Cautiously Upbeat For Investment Year Ahead – BioWales 2024
Favorable UK biopharma investment trends have been reported by the BioIndustry Association, but can medtech and healthtech share in the positivity? A roundtable at the BioWales in London 2024 event framed the outlook for non-pharma players.